Scientific Health Development

Scientific Health Development Ltd. is a boutique investment firm based in Dallas, Texas, founded in 2006. The company specializes in early-stage investments, focusing on innovative healthcare-related technologies, products, and services within the health, science, medical, and wellness sectors. It typically invests up to $0.2 million in each portfolio company, often before their products are ready for public availability. Scientific Health Development aims to support the growth of promising ventures in the U.S. healthcare landscape while allowing its investors the opportunity to co-invest in these emerging companies.

Stuart Fitts

Co-Founder and General Partner

23 past transactions

SecondWave Systems

Series A in 2025
SecondWave Systems develops an ultrasound stimulation platform that will give patients and their physicians a new option for treating debilitating or life-threatening diseases. Their technology utilizes non-invasive, low-intensity focused ultrasound to modulate nerves, cells, and organs deep within the body. They provide technology that suppresses neural and cellular pathways with the potential to treat many conditions, including inflammation, pain, and a variety of other disorders.

Liberate Medical

Series B in 2023
Liberate Medical, LLC is a medical device company focused on improving the treatment of patients with chronic obstructive pulmonary disease (COPD) by developing innovative technologies. Founded in 2013 and based in Crestwood, Kentucky, the company has created VentFree, a system that utilizes non-invasive neuromuscular electrical stimulation to contract abdominal wall muscles in sync with a patient’s breathing. This approach aims to minimize disuse atrophy of these muscles, potentially decreasing the duration of mechanical ventilation required for adult patients. By enhancing respiratory muscle function, Liberate Medical seeks to improve patient outcomes and reduce healthcare costs associated with pulmonary disorders.

Podimetrics

Series C in 2022
Podimetrics, Inc. is a care management company focused on preventing diabetic foot ulcers, a significant complication of diabetes. Founded in 2011 and headquartered in Somerville, Massachusetts, Podimetrics has developed the SmartMat, a wireless monitoring system that allows patients to scan their foot temperatures at home for just 20 seconds daily. This FDA-cleared device automatically transmits data to the company's clinical support team, which monitors for any concerning findings. By integrating advanced technology with effective care management, Podimetrics enhances patient engagement and enables clinicians to achieve improved health outcomes, ultimately saving limbs, lives, and healthcare costs. The company is supported by notable investors, including Norwich Ventures and Rock Health.

Koya Medical

Series B in 2022
Koya Medical, Inc., founded in 2018 and based in Oakland, California, specializes in developing innovative therapeutic devices aimed at treating cancer-related chronic lymphedema and various venous diseases. The company focuses on creating wearable technology that delivers active compression therapy, which is designed to enhance movement and mobility for patients. Koya Medical's approach offers a personalized alternative to traditional compression methods, utilizing a sensor-based closed-loop system to provide tailored compression patterns. This technology addresses the needs of patients suffering from conditions such as lymphedema, chronic edema, and chronic venous insufficiency, thereby improving their quality of care and overall treatment outcomes.

Empirical Spine

Series B in 2021
Empirical Spine, Inc. is a medical device company based in San Carlos, California, that specializes in the development of a stabilization system for orthopedic and spinal surgery. The company's flagship product, LimiFlex, is a paraspinous tension band designed to stabilize the spine without compromising its function, specifically targeting patients with degenerative lumbar spinal disorders. This minimally invasive device is particularly beneficial for individuals suffering from spinal stenosis and grade I degenerative spondylolisthesis, providing healthcare providers with effective tools for secure spinal surgeries. Empirical Spine was incorporated in 2015 and continues to focus on innovative solutions in spinal care.

MiNDERA Corporation

Series A in 2021
MiNDERA Corporation specializes in the development of non-invasive molecular testing devices aimed at diagnosing skin cancer and other skin diseases. The company's innovative products include a micro-needle array patch that allows for pain-free and minimally invasive extraction of biomarkers such as RNA, DNA, and proteins from the skin, eliminating the need for traditional skin biopsies. Additionally, MiNDERA is working on a whole transcriptome extraction patch and a skin microbiome extraction patch for various research applications. Founded in 2013, the company is headquartered in Palo Alto, California.

Koya Medical

Venture Round in 2020
Koya Medical, Inc., founded in 2018 and based in Oakland, California, specializes in developing innovative therapeutic devices aimed at treating cancer-related chronic lymphedema and various venous diseases. The company focuses on creating wearable technology that delivers active compression therapy, which is designed to enhance movement and mobility for patients. Koya Medical's approach offers a personalized alternative to traditional compression methods, utilizing a sensor-based closed-loop system to provide tailored compression patterns. This technology addresses the needs of patients suffering from conditions such as lymphedema, chronic edema, and chronic venous insufficiency, thereby improving their quality of care and overall treatment outcomes.

Podimetrics

Series B in 2020
Podimetrics, Inc. is a care management company focused on preventing diabetic foot ulcers, a significant complication of diabetes. Founded in 2011 and headquartered in Somerville, Massachusetts, Podimetrics has developed the SmartMat, a wireless monitoring system that allows patients to scan their foot temperatures at home for just 20 seconds daily. This FDA-cleared device automatically transmits data to the company's clinical support team, which monitors for any concerning findings. By integrating advanced technology with effective care management, Podimetrics enhances patient engagement and enables clinicians to achieve improved health outcomes, ultimately saving limbs, lives, and healthcare costs. The company is supported by notable investors, including Norwich Ventures and Rock Health.

Procyrion

Series D in 2019
Procyrion, Inc. is a clinical-stage medical device company based in Houston, Texas, specializing in the development of circulatory assist technologies. Founded in 2005, the company has created the Aortix Heart Pump, a non-surgical, catheter-deployed device designed for patients suffering from heart failure who cannot be adequately treated with medication alone. This innovative pump is implanted through a catheter inserted in the leg and is positioned between the heart and kidneys to alleviate the burden on the failing heart and improve organ perfusion. By addressing cardiorenal syndrome, Aortix aims to relieve symptoms of heart failure, particularly for patients who are diuretic resistant or in acute decompensation. The device's design allows it to be less invasive than traditional options, providing a critical solution for the significant number of adults over 40 who may face heart failure in their lifetime.

Podimetrics

Series B in 2019
Podimetrics, Inc. is a care management company focused on preventing diabetic foot ulcers, a significant complication of diabetes. Founded in 2011 and headquartered in Somerville, Massachusetts, Podimetrics has developed the SmartMat, a wireless monitoring system that allows patients to scan their foot temperatures at home for just 20 seconds daily. This FDA-cleared device automatically transmits data to the company's clinical support team, which monitors for any concerning findings. By integrating advanced technology with effective care management, Podimetrics enhances patient engagement and enables clinicians to achieve improved health outcomes, ultimately saving limbs, lives, and healthcare costs. The company is supported by notable investors, including Norwich Ventures and Rock Health.

Procyrion

Series C in 2018
Procyrion, Inc. is a clinical-stage medical device company based in Houston, Texas, specializing in the development of circulatory assist technologies. Founded in 2005, the company has created the Aortix Heart Pump, a non-surgical, catheter-deployed device designed for patients suffering from heart failure who cannot be adequately treated with medication alone. This innovative pump is implanted through a catheter inserted in the leg and is positioned between the heart and kidneys to alleviate the burden on the failing heart and improve organ perfusion. By addressing cardiorenal syndrome, Aortix aims to relieve symptoms of heart failure, particularly for patients who are diuretic resistant or in acute decompensation. The device's design allows it to be less invasive than traditional options, providing a critical solution for the significant number of adults over 40 who may face heart failure in their lifetime.

Channel Medsystems

Series C in 2017
Channel Medsystems, Inc. is a medical device company focused on women's healthcare, specifically in the area of endometrial ablation. Founded in 2009 and based in Emeryville, California, the company specializes in developing cryothermic technology that integrates cryothermic energy into a user-friendly, handheld device. This innovative delivery system allows for effective endometrial cryoablation without the need for separate control units or extensive capital equipment, making it more accessible for patients and healthcare providers. Channel Medsystems aims to empower women to take control of their health by providing cutting-edge solutions that enhance their healthcare experience.

MiNDERA Corporation

Seed Round in 2016
MiNDERA Corporation specializes in the development of non-invasive molecular testing devices aimed at diagnosing skin cancer and other skin diseases. The company's innovative products include a micro-needle array patch that allows for pain-free and minimally invasive extraction of biomarkers such as RNA, DNA, and proteins from the skin, eliminating the need for traditional skin biopsies. Additionally, MiNDERA is working on a whole transcriptome extraction patch and a skin microbiome extraction patch for various research applications. Founded in 2013, the company is headquartered in Palo Alto, California.

Sight Sciences

Series A in 2015
Sight Sciences is a medical device company specializing in ophthalmic devices and glaucoma implants aimed at treating irreversible blindness. Headquartered in Menlo Park, California, the company has developed the OMNI Surgical System, which allows for targeted treatment of glaucoma by addressing three points of resistance with a single device and incision. Additionally, Sight Sciences offers TearCare, a wearable technology that delivers adjustable thermal energy to the meibomian glands to treat conditions like dry eye and meibomian gland dysfunction. The company also provides SmartLid, which aids in the natural expression of meibum when it is in a melted state. Founded in 2010, Sight Sciences focuses on both surgical and non-surgical technologies to address prevalent eye diseases and has a commercial office in Southlake, Texas.

MiNDERA Corporation

Seed Round in 2015
MiNDERA Corporation specializes in the development of non-invasive molecular testing devices aimed at diagnosing skin cancer and other skin diseases. The company's innovative products include a micro-needle array patch that allows for pain-free and minimally invasive extraction of biomarkers such as RNA, DNA, and proteins from the skin, eliminating the need for traditional skin biopsies. Additionally, MiNDERA is working on a whole transcriptome extraction patch and a skin microbiome extraction patch for various research applications. Founded in 2013, the company is headquartered in Palo Alto, California.

Procyrion

Series B in 2015
Procyrion, Inc. is a clinical-stage medical device company based in Houston, Texas, specializing in the development of circulatory assist technologies. Founded in 2005, the company has created the Aortix Heart Pump, a non-surgical, catheter-deployed device designed for patients suffering from heart failure who cannot be adequately treated with medication alone. This innovative pump is implanted through a catheter inserted in the leg and is positioned between the heart and kidneys to alleviate the burden on the failing heart and improve organ perfusion. By addressing cardiorenal syndrome, Aortix aims to relieve symptoms of heart failure, particularly for patients who are diuretic resistant or in acute decompensation. The device's design allows it to be less invasive than traditional options, providing a critical solution for the significant number of adults over 40 who may face heart failure in their lifetime.

MiNDERA Corporation

Grant in 2015
MiNDERA Corporation specializes in the development of non-invasive molecular testing devices aimed at diagnosing skin cancer and other skin diseases. The company's innovative products include a micro-needle array patch that allows for pain-free and minimally invasive extraction of biomarkers such as RNA, DNA, and proteins from the skin, eliminating the need for traditional skin biopsies. Additionally, MiNDERA is working on a whole transcriptome extraction patch and a skin microbiome extraction patch for various research applications. Founded in 2013, the company is headquartered in Palo Alto, California.

Channel Medsystems

Series C in 2015
Channel Medsystems, Inc. is a medical device company focused on women's healthcare, specifically in the area of endometrial ablation. Founded in 2009 and based in Emeryville, California, the company specializes in developing cryothermic technology that integrates cryothermic energy into a user-friendly, handheld device. This innovative delivery system allows for effective endometrial cryoablation without the need for separate control units or extensive capital equipment, making it more accessible for patients and healthcare providers. Channel Medsystems aims to empower women to take control of their health by providing cutting-edge solutions that enhance their healthcare experience.

AlgoMedica

Series A in 2015
AlgoMedica, Inc. is a medical imaging software company specializing in solutions that significantly reduce radiation exposure during CT scans. The company has developed PixelShine, a software solution that operates on server or cloud platforms to enhance CT images captured at only 10% of the standard radiation dose. Utilizing advanced image enhancing and noise reduction technologies based on artificial neural networks, PixelShine improves the quality of these low-dose images, making them comparable to those taken under standard protocols. This technology is versatile and can be applied to various body parts, including the abdomen, pelvis, head, liver, and pediatric imaging. Established in 2012, AlgoMedica is headquartered in Palo Alto, California, and aims to provide medical facilities with advanced imaging capabilities while minimizing radiation exposure for patients.

Complexa

Series A in 2012
Complexa, Inc. is a biopharmaceutical company based in Berwyn, Pennsylvania, focused on developing treatments for severe and life-threatening diseases related to fibrosis and inflammation. Established in 2008, the company is advancing its lead compound, CXA-10, an oral nitrated fatty acid aimed at treating focal segmental glomerulosclerosis (FSGS) and pulmonary arterial hypertension (PAH). Complexa utilizes proprietary technologies that involve the synthesis of endogenous nitro-fatty acids, which serve as cell-signaling agents regulating key inflammatory pathways. This approach aims to enhance the body's natural mechanisms for resolving and repairing acute and chronic tissue injuries, with a focus on addressing various inflammatory, fibrotic, and central nervous system diseases.

EMKinetics

Series C in 2011
EMKinetics, Inc. is a clinical-stage medical technology company based in San Francisco, California, specializing in the development of neuromodulation therapies utilizing its proprietary Transdermal Stimulation (TranStim) technology. This innovative approach aims to provide effective treatment for conditions such as overactive bladder and urinary incontinence by delivering electric pulses that facilitate neuromodulation. Founded in 2006, EMKinetics focuses on advancing its therapies to improve patient outcomes in managing these health issues.

EMKinetics

Venture Round in 2010
EMKinetics, Inc. is a clinical-stage medical technology company based in San Francisco, California, specializing in the development of neuromodulation therapies utilizing its proprietary Transdermal Stimulation (TranStim) technology. This innovative approach aims to provide effective treatment for conditions such as overactive bladder and urinary incontinence by delivering electric pulses that facilitate neuromodulation. Founded in 2006, EMKinetics focuses on advancing its therapies to improve patient outcomes in managing these health issues.

CureDM

Series B in 2006
CureDM, Inc. is a biopharmaceutical company based in Wilmington, Delaware, focused on developing and commercializing innovative therapies aimed at preventing, ameliorating, or reversing diabetes. Established in 2004, the company is dedicated to addressing both Type 1 and Type 2 diabetes through its lead product, Pancreate, a human peptide therapeutic. This drug candidate targets the regeneration of insulin-producing islets in the pancreas, with the potential to allow patients to discontinue insulin therapy.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.